Publications by authors named "Dian-Yu Zheng"
Article Synopsis
- - The study investigates the effects of Vedolizumab (VDZ) on extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD), focusing on the resolution of pre-existing EIMs during treatment.
- - Out of 21 studies analyzed, 39% of VDZ-treated patients experienced resolution of their pre-existing EIMs, while rates of exacerbations and new onset EIMs were reported at 28% and 15%, respectively.
- - VDZ is effective for certain skin and joint-related EIMs, particularly erythema nodosum and arthritis, although some patients may see an increase in EIMs during treatment.
Background: Upadacitinib, a novel and selective inhibitor of Janus kinase 1, has demonstrated promising efficacy in managing inflammatory bowel disease (IBD). In this systematic review and meta-analysis, our primary aim was to comprehensively assess the therapeutic effectiveness and safety profile of upadacitinib in the treatment of patients with IBD.
Methods: We conducted an extensive literature search across prominent databases, including Medline, Embase, Web of Science, and Cochrane Central, to identify pertinent studies providing insights into the efficacy and safety of upadacitinib in IBD.